Loading...
XNAS
OTLK
Market cap88mUSD
Jul 11, Last price  
2.07USD
1D
2.48%
1Q
50.00%
IPO
-98.13%
Name

Outlook Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
82.77%
Rev. gr., 5y
9.32%
Revenues
0k
9,050,5425,219,2372,979,5763,811,5193,087,5608,146,12200000
Net income
-75m
L+27.78%
-13,732,473-47,393,283-53,329,262-38,849,127-46,114,924-34,523,787-35,239,000-53,163,000-66,052,264-58,982,668-75,366,714
CFO
-68.79t
L+160,084,652.90%
-7,020,469-27,476,200-45,482,672-15,505,0540-32,289,988-31,790,093-54,253,288-56,674,559-42,973,398-68,793,858,000,000
Earnings
Aug 12, 2025

Profile

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
URL
https://outlooktherapeutics.com/
IPO date
Jun 13, 2016
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
71,703
53,171
63,275
Unusual Expense (Income)
NOPBT
(71,703)
(53,171)
(63,275)
NOPBT Margin
Operating Taxes
3
3
Tax Rate
NOPAT
(71,703)
(53,173)
(63,278)
Net income
(75,367)
27.78%
(58,983)
-10.70%
(66,052)
24.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
60,334
30,024
62,307
BB yield
-60.91%
-54.30%
-24.08%
Debt
Debt current
29,491
35,555
10,954
Long-term debt
545
4
47
Deferred revenue
Other long-term liabilities
59,345,934,753
6
57
Net debt
(14,927,507,964)
11,374
(7,201)
Cash flow
Cash from operating activities
(68,793,858,000)
(42,973)
(56,675)
CAPEX
(2)
Cash from investing activities
Cash from financing activities
60,329,414,000
48,969
59,594
FCF
14,862,944,975
(51,782)
7,030,752,800
Balance
Cash
14,927,538,000
23,392
17,397
Long term investments
794
805
Excess cash
14,927,538,000
24,186
18,202
Stockholders' equity
(543,284,899,761)
(465,316)
28,527,762,010
Invested Capital
529,554,354,252
486,439
(307)
ROIC
ROCE
0.00%
EV
Common stock shares outstanding
18,549
12,509
10,604
Price
5.34
20.81%
4.42
-81.89%
24.40
-43.78%
Market cap
99,051
79.15%
55,289
-78.63%
258,737
-21.90%
EV
(14,927,408,914)
66,663
28,528,002,536
EBITDA
113,787,297
(53,126)
(63,071)
EV/EBITDA
Interest
1,560
1,487
Interest/NOPBT